Managed Account Advisors’s Vanda Pharmaceuticals VNDA Stock Holding History

Managed Account Advisors’s Portfolio VNDA Stock Details VNDA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q2	$165K	Buy	12,968 +4,114	+46%	+$44.4K	﹤0.01%	2527
2015 Q1	$82K	Buy	+8,854	New	+$100K	﹤0.01%	2567
2013 Q4	–	Sell	-7,676	Closed	-$84K	–	2600
2013 Q3	$84K	Buy	+7,676	New	+$82K	﹤0.01%	2238

Other funds holding VNDA

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

KCM

Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

Managed Account Advisors's VNDA Position: Q2 2015 in Review

Managed Account Advisors increased its Vanda Pharmaceuticals (VNDA) stake by 46% in Q2 2015, buying an estimated $44.4K and bringing the position to 12,968 shares worth $165K. The position accounts for ﹤0.01% of the portfolio, ranked #2527.

Managed Account Advisors first reported a position in VNDA in Q3 2013 and has held it in 3 quarters since. 109 funds tracked by Wall St. Rank hold VNDA as of Q2 2015.

Managed Account Advisors held 12,968 shares of Vanda Pharmaceuticals worth $165K as of Q2 2015.
Managed Account Advisors bought 4,114 Vanda Pharmaceuticals shares in Q2 2015, an estimated $44.4K.
Vanda Pharmaceuticals made up ﹤0.01% of Managed Account Advisors's portfolio in Q2 2015, its #2527 holding.
Managed Account Advisors first reported a position in Vanda Pharmaceuticals in Q3 2013 and has held it in 3 quarters since.
109 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q2 2015.

Based on Managed Account Advisors's 13F filing for Q2 2015, filed 14 Aug 2015.